Florian Bassermann - Cell Biology of Cancer
Research in our lab focuses on the molecular pathophysiology and evolution of malignant diseases, particularly hematological neoplasms, such as B-cell malignancies and acute leukemias, as well as selected solid entities including lung cancer. Functionally, we focus on aberrant ubiquitin-dependent signaling pathways and other posttranslational mechanisms, which play pivotal roles in the regulation of tumor-relevant cellular processes such as cell cycle regulation, DNA damage response, immune responses, cell metabolism and programmed cell death and protein quality control.
Starting from a discovery-driven approach that combines multi-OMIC technologies (tumor genomics and functional proteomics) with cell biology, preclinical mouse models and analyses in large, defined patient cohorts, our central task is to forward our new functional insights to direct translational application. To this end, we define and validate new therapeutic target structures and engage in respective drug development efforts, either in academia or in collaboration with pharmaceutical companies, to develop new treatment strategies that are investigated in early clinical trials.
Florian Bassermann is the director of the department of hematology and oncology at the University hospital Klinikum Rechts der Isar in Munich. He studied medicine in Ulm, Munich and New York and obtained his Ph.D. from TUM in 2002. After clinical activities and working as a research scientist at TUM, he took up a postdoctoral position at New York University in 2006. On his return to TUM in 2009, he became head of a German Research Foundation- (DFG-) funded Emmy Noether junior research group, completed his training leading to German medical board certification in internal medicine and hematology/oncology, and acquired his postdoctoral teaching qualification (habilitation). In 2011, he was appointed to the position of senior physician, and in 2015, he took up a tenure track professorship at TUM. In 2017, he became the head of the department of hematology and oncology. His lab moved to the newly built TranslaTUM institute in 2018.
- Member of the Scientific Advisory Board of the Jose Carreras Leukemia Foundation (2021)
- Spokesperson of the TUM site of the Bavarian Cancer Research Center (BZKF) (2019)
- Vice Spokesperson SFB 1335 “Aberrant immune signals in cancer” (2018)
- Galenus von Pergamon Research award (2017)
- Consolidator Grant from the European Research Council (2015)
- Langener Science Award from the Paul Ehrlich Institute (2015)
- Theodor Frerichs Prize from the German Society of Internal Medicine, DGIM (2015)
- Walther Flemming Medal from the German Society of Cellular Biology, DGZ (2010)
- Emmy Noether Program from the German Research Foundation, DFG (2008)
- AACR-Astellas USA Foundation Fellowship in Basic Cancer Research from the American Association of Cancer Research (2008)
Stroh, J., Seckinger, A., Heider, M., Rudelius, M., Eichner, R., Schick, M., Slawska, J., Emde-Rajaratnam, M., Salwender, H., Bertsch, U., Goldschmidt, H., Weisel, K., Scheid, C., Keller, U., Hose, D., Bassermann, F. (2022). MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma. Blood Adv 6, 515-520.
Heider, M., Eichner, R., Stroh, J., Morath, V., Kuisl, A., Zecha, J., Lawatscheck, J., Baek, K., Garz, A.K., Rudelius, M., Deuschle, F.C., Keller, U., Lemeer, S., Verbeek, M., Gotze, K.S., Skerra, A., Weber, W.A., Buchner, J., Schulman, B.A., Kuster, B., Fernandez-Saiz, V., Bassermann, F. (2021). The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma. Mol Cell 81, 1170-1186 e10.
Dietachmayr, M., Rathakrishnan, A., Karpiuk, O., von Zweydorf, F., Engleitner, T., Fernandez-Saiz, V., Schenk, P., Ueffing, M., Rad, R., Eilers, M., Gloeckner, C.J., Clemm von Hohenberg, K., Bassermann, F. (2020). Antagonistic activities of CDC14B and CDK1 on USP9X regulate WT1-dependent mitotic transcription and survival. Nat Commun 11, 1268.
Eichner, R., Heider, M., Fernandez-Saiz, V., van Bebber, F., Garz, A.K., Lemeer, S., Rudelius, M., Targosz, B.S., Jacobs, L., Knorn, A.M., Slawska, J., Platzbecker, U., Germing, U., Langer, C., Knop, S., Einsele, H., Peschel, C., Haass, C., Keller, U., Schmid, B., Gotze, K.S., Kuster, B., Bassermann, F. (2016). Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity. Nat Med 22, 735-43.
Engel, K., Rudelius, M., Slawska, J., Jacobs, L., Ahangarian Abhari, B., Altmann, B., Kurutz, J., Rathakrishnan, A., Fernandez-Saiz, V., Brunner, A., Targosz, B.S., Loewecke, F., Gloeckner, C.J., Ueffing, M., Fulda, S., Pfreundschuh, M., Trumper, L., Klapper, W., Keller, U., Jost, P.J., Rosenwald, A., Peschel, C., Bassermann, F. (2016). USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B-cell lymphoma. EMBO Mol Med 8, 851-62.
Baumann, U., Fernandez-Saiz, V., Rudelius, M., Lemeer, S., Rad, R., Knorn, A.M., Slawska, J., Engel, K., Jeremias, I., Li, Z., Tomiatti, V., Illert, A.L., Targosz, B.S., Braun, M., Perner, S., Leitges, M., Klapper, W., Dreyling, M., Miething, C., Lenz, G., Rosenwald, A., Peschel, C., Keller, U., Kuster, B., Bassermann, F. (2014). Disruption of the PRKCD-FBXO25-HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis. Nat Med 20, 1401-9.
Dechow, T., Steidle, S., Gotze, K.S., Rudelius, M., Behnke, K., Pechloff, K., Kratzat, S., Bullinger, L., Fend, F., Soberon, V., Mitova, N., Li, Z., Thaler, M., Bauer, J., Pietschmann, E., Albers, C., Grundler, R., Schmidt-Supprian, M., Ruland, J., Peschel, C., Duyster, J., Rose-John, S., Bassermann, F., Keller, U. (2014). GP130 activation induces myeloma and collaborates with MYC. J Clin Invest 124, 5263-74.
Fernandez-Saiz, V., Targosz, B.S., Lemeer, S., Eichner, R., Langer, C., Bullinger, L., Reiter, C., Slotta-Huspenina, J., Schroeder, S., Knorn, A.M., Kurutz, J., Peschel, C., Pagano, M., Kuster, B., Bassermann, F. (2013). SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma. Nat Cell Biol 15, 72-81.
Bassermann, F., Frescas, D., Guardavaccaro, D., Busino, L., Peschiaroli, A., Pagano, M. (2008). The Cdc14B-Cdh1-Plk1 axis controls the G2 DNA-damage-response checkpoint. Cell 134, 256-67.
Bassermann, F., von Klitzing, C., Munch, S., Bai, R.Y., Kawaguchi, H., Morris, S.W., Peschel, C., Duyster, J. (2005). NIPA defines an SCF-type mammalian E3 ligase that regulates mitotic entry. Cell 122, 45-57.